MERAIODE: A Phase II Redifferentiation Trial with Trametinib and 131I in Metastatic Radioactive Iodine Refractory RAS Mutated Differentiated Thyroid Cancer - Centre Antoine Lacassagne
Journal Articles Thyroid Year : 2023

MERAIODE: A Phase II Redifferentiation Trial with Trametinib and 131I in Metastatic Radioactive Iodine Refractory RAS Mutated Differentiated Thyroid Cancer

Nadege Anizan

Abstract

No abstract available
Embargoed file
Embargoed file
Visibility date is undetermined

Dates and versions

inserm-04527070 , version 1 (29-03-2024)

Licence

Copyright

Identifiers

Cite

Sophie Leboulleux, Daniele Benisvy, David Taieb, Marie Attard, Claire Bournaud, et al.. MERAIODE: A Phase II Redifferentiation Trial with Trametinib and 131I in Metastatic Radioactive Iodine Refractory RAS Mutated Differentiated Thyroid Cancer. Thyroid, 2023, 33 (9), pp.1124-1129. ⟨10.1089/thy.2023.0240⟩. ⟨inserm-04527070⟩
146 View
4 Download

Altmetric

Share

More